Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INX 3280

Drug Profile

INX 3280

Alternative Names: LR 3280; TA 3280

Latest Information Update: 09 Dec 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Inex Pharmaceuticals Corporation; Tanabe Seiyaku
  • Class Antisense oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lymphoma; Reperfusion injury; Solid tumours

Most Recent Events

  • 08 Dec 2004 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 17 Jun 2002 Discontinued - Phase-II for Lymphoma in Canada (unspecified route)
  • 17 Jun 2002 Discontinued - Phase-II for Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top